DeciBio

August was a busy month for the next-generation therapeutics field. In the Cell Therapy space, Galapagos halted their multiple myeloma trial due to a neurological concern, while Avenge Bio shut down their company and bluebird bio announced increased financial strain due to slow sales for their sickle cell therapy Lyfgenia. In the Gene Therapy space, Tome Biosciences announced they were laying off their entire team and Lacerta Therapeutics announced they were shutting down operations. Beacon Therapeutics also announced Lance Baldo’s appointment at CEO, while the FDA lifted a clinical trial hold on 4DMT’s Fabry Program.   In the Oligo Therapy space, Innovent Biologics and Sanegene Bio dosed their first patient in a Phase 1 trial of IBI3016 and BioNTech SE dosed their first patient in a Phase 1 trial with a mRNA cancer vaccine for NSCLC. VION Biosciences also announced their acquisition of Echelon Biosciences to target customers in mRNA therapeutics delivery. Multiple partnership updates were announced in the ADC space, with Adcendo and Multitude Therapeutics teaming up, Daiichi Sankyo and Merck Group announcing a partnership, and ArriVent Biopharma announcing their decision to exercise the option to exclusively license a program from Aarvik Therapeutics Inc. Read on to see additional developments that occurred in August here: https://lnkd.in/eYTFPbu8 Subscribe to our newsletter on Linkedin: https://lnkd.in/gMfy6_YZ Sign up to receive our Next-Generation Therapeutics Newsletter in your email: https://lnkd.in/gKQn7_zp These headlines were curated by Rebecca Burnham, PhD, Hannah Glazier, Luka Jelcic, Juilee Malavade, Ph.D., Carl Schoellhammer, and Ben Yarovinsky. #precisionmedicine #nextgenerationtherapeutics #celltherapy #genetherapy #oligotherapy #innovation #biotechnology

The European Society of Medical Oncology annual meeting is just around the corner. Who's headed to Barcelona this year for the conference? September 13-17, 2024

This month at DeciBio, it's all eyes on #digitalpathology In anticipation of publishing the 2nd edition of our digital pathology market report, we're hosting a webinar this Thursday on the Oncologist's Role in the Digital Pathology Revolution Thursday, September 5, 2024 7:00 AM PT / 10:00 AM ET Registration: https://lnkd.in/gX2ZmSU8 Our updated report provides an overview of the digital pathology market from 2024 to 2029. The digital pathology market, as defined in this report, is comprised of revenue from instruments and software sold to clinical, academic, biopharma, and CRO customers, along with service revenues generated by CROs and reference labs. In the meantime, check out our updated #digitalpathology landscape visual highlighting a number of new AI / IA entrants gaining traction in the field.

Join us next week for a webinar on "The Oncologist's Role in the Digital Pathology Revolution" Date: Thursday, September 5, 2024 Time: 7:00 AM PT / 10:00 AM ET Registration: https://lnkd.in/gDfCPc84 Digital pathology tools have reshaped lab operations, but as new technologies emerge, the focus is shifting towards clinical applications. Learn how oncologists are helping shape these discussions, becoming increasingly central to the integration of these tools into patient care. In this discussion, we'll address the barriers to adopting digital pathology tools in clinical settings, offer practical solutions, and explore how workflow and diagnostic advancements can directly enhance patient care. Our expert panel will provide key perspectives on the future of digital pathology from both lab and clinical viewpoints. Featured Speakers: Charles Gaulin, MD Anderson Cancer Center Joseph Annunziata, M.D. Medical Director, Molecular Pathologist Omar Perez, AstraZeneca Heinz-Josef Klümpen Medical Oncologist and Consultant This panel of leading oncologists and molecular pathologists will offer diverse perspectives on how digital pathology is transforming the future of cancer care. Our Updated Digital & Computational Pathology Report is also coming soon. Pre-purchase now to lock in a 10% early-bird discount: https://lnkd.in/dxxw_hTt

Missed our webinar on the Future of Clinical Oncology NGS earlier this week? You can now watch the full session on demand on our website here: https://lnkd.in/gafuCD75 We covered critical topics such as insourcing challenges, the economics of costs and reimbursement, comprehensive vs. targeted approaches, solid vs. liquid biopsies, cancer germline testing, and the emerging role of multiomics in clinical oncology. A big thank you to our esteemed panelists for their invaluable insights and to our engaged audience for your thoughtful questions. If your question wasn’t addressed during the session, stay tuned! We’ll be diving deeper into these topics in a follow-up series over the next few weeks. Make sure to turn on notifications so you don’t miss out! #ClinicalNGS #NGS #PrecisionMedicine

Radiomics is gaining momentum as a transformative tool in medical research and clinical practice. In this latest Q&A, Onc.AI CEO Akshay Nanduri shares insights on the advancements pushing radiomics from research to clinical application. Explore how AI-driven innovations are reshaping oncology and beyond in our newest blog: 'Radiomics: The Intersection of Modern Deep Learning and Clinical Imaging.' https://lnkd.in/gjDhKDJm This kicks off Tina Wang ongoing series on #radiomics, with this blog co-authored by Benjamin Zaidel. Stay tuned for more interviews highlighting the latest breakthroughs in the field.

Digital pathology tools have revolutionized lab operations, but the conversation is shifting. As emerging tools increasingly target clinical questions, there's a growing opportunity to bring oncologists into the discussion. In this webinar, we'll explore the hurdles to the adoption of these tools, practical solutions to overcome these challenges, and insights from a lab medicine perspective on how workflow and diagnostic tools can improve patient outcomes. Moderators Katie Maloney, DeciBio Esther Abels, SolarisRTC We’ve invited oncologists and molecular pathologists to join the discussion, offering diverse perspectives on the future of digital pathology. Stay tuned for the full announcement of our expert panelists! Date: Thursday, September 5, 2024 Time: 7:00 AM PT / 10:00 AM ET Register with the link here: https://lnkd.in/gjFTXMYN Our Updated Digital & Computational Pathology Report is Coming Soon! Pre-purchase now and lock in a 10% early-bird discount! Head over to our website to take advantage of this offer: https://lnkd.in/dxxw_hTt Sign up to be notified when the report is published and gain early access: https://lnkd.in/gc-Z98dN #DigitalPathology #Webinar #PrecisionMedicine

Join Us Tomorrow for the Future of Clinical Oncology NGS Webinar: Decentralized vs. Centralized We're excited to bring together industry leaders to discuss the evolving landscape of clinical oncology NGS. Don't miss this conversation! Webinar Details 📅 Tuesday, August 20, 2024 🕘 9:00 AM - 10:00 AM PT Registration Link: https://lnkd.in/gv56-Yrj A special thank you to our esteemed panelists for sharing their expertise: Amber Leigh (Fehrs-Battey) Jerome (Rome) Madison Dave Westenberg, CFA George W. Daneker, Jr. MD Vik Vaz, M.D. Shawn Levy Before the webinar, be sure to cast your vote in our polls on decentralization vs. centralization across key areas such as treatment selection, MRD, early detection, and hereditary cancer germline testing. See you there! #PrecisionMedicine #ClinicalOncology #NGS

Minimal Residual Disease, Surveillance, and Monitoring In our recently published Oncology Liquid Biopsy Market report, we found that the combined market for MRD, surveillance, and monitoring is expected to hold the largest share of the liquid biopsy market, with an anticipated annual growth rate of 31% through 2029. As we conclude our 4-part poll series leading up to the webinar on the Future of Clinical Oncology NGS, today’s focus is on MRD, surveillance, and monitoring. With new indications for MRD emerging beyond #CRC, improved access and reimbursement, and an increasing number of assays and platforms entering the space, what is your perspective on the democratization of MRD? Do you foresee MRD remaining concentrated among a few centralized players, or will innovations in technology drive decentralization in the U.S. over the next five years?

Earlier this year, #ASCO released updated guidelines for ordering multigene panels for germline genetic testing in cancer patients. As part of our 4-part poll series leading up to our webinar on the Future of Clinical Oncology NGS, today’s focus is on hereditary cancer germline testing. Historically, only a few centralized groups have dominated the hereditary cancer germline testing space. However, with increasing clinical evidence and new guidelines highlighting its utility, more players are entering the field. Given these developments, how do you see the landscape of hereditary cancer germline testing evolving in the U.S. over the next five years? Will it trend toward centralization, decentralization, or remain unchanged? We'll be discussing this plus more with members of two of the most prominent HCT providers in the industry on our webinar next week. Join us! Tuesday, August 20 at 9:00 AM PT Register Here: https://lnkd.in/gSCxCcKA